Cullgen’s oncology portfolio features TRK, GSPT1 and CDK2 degraders.
ApexOnco Front Page
Recent articles
But now it must show that varseta-M can move into a registrational trial.
The first fruit of a long-standing deal with Roche enters phase 1 in March.
Welireg looks headed to regulators in second-line and adjuvant kidney cancer.
The company will license EGFR and cMet inhibitors from Celyn.
The combo gets another slam dunk, this time in perioperative chemo-eligible MIBC.
After several discontinuations, a new ADC enters the clinic.
TARA-002 goes from looking better than Inlexzo to seeming rather worse.
